6 completed. 6 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 6 | Completed 6 |
Follow Risk-Taking: new trials by email Literature Review of Risk-Taking trials Research Report on Risk-Taking
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DOT Diary Mobile App for Pre-Exposure Prophylaxis Adherence in Young Men Emtricitabine / Tenofovir Disoproxil Oral Tablet, DOT Diary mobile app - Adherence, Medication, Risk Behavior | Phase 4 | Completed | Public Health Foundation Enterprises, Inc. | 100 | 2019-02-01 | 2025-07-03 |
| DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP Adherence Emtricitabine / Tenofovir Disoproxil Oral Tablet, DOT Diary mobile app - Adherence, Medication, Risk Behavior | Phase 4 | Completed | Public Health Foundation Enterprises, Inc. | 20 | 2018-02-28 | 2021-10-27 |
| Behavioural Addictions Occurring During a Dopaminergic Treatment Prescribe Under Parkinson's Disease: Study of the Psychopathological, Neurological, Pharmacokinetic and Genetic Profiles questionnaires - Parkinson's Disease, Secondary Behavioural Addiction | Phase 4 | Completed | Nantes University Hospital | 225 | 2012-10-01 | 2018-02-15 |
| Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention Naltrexone pharmacotherapy, Placebo - Pathological Gambling | Phase 4 | Completed | Finnish Institute for Health and Welfare | 100 | 2011-01-01 | 2013-12-05 |
| Naltrexone for Impulse Control Disorders in Parkinson's Disease Naltrexone, Placebo - Impulse Control Disorder, Parkinson Disease | Phase 4 | Completed | University of Pennsylvania | 50 | 2009-11-01 | 2015-08-06 |
| Acamprosate in the Treatment of Pathological Gambling acamprosate - Pathological Gambling | Phase 4 | Completed | University of Iowa | 26 | 2007-10-01 | 2017-05-25 |
Gambling (4) · Disruptive, Impulse Control, and Conduct Disorders (2) · Medication Adherence (2) · Parkinson Disease (2) · Compulsive Sexual Behavior Disorder (1) · Food Addiction (1)
Behavior (6) · Mental Disorders (4) · Basal Ganglia Diseases (2) · Brain Diseases (2) · Central Nervous System Diseases (2) · Disruptive, Impulse Control, and Conduct Disorders (2) · Health Behavior (2) · Movement Disorders (2) · Nervous System Diseases (2) · Neurodegenerative Diseases (2) · Parkinsonian Disorders (2) · Patient Acceptance of Health Care (2) · Patient Compliance (2) · Synucleinopathies (2)
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (2) · Acamprosate (1) · Naltrexone (1) · Surveys and Questionnaires (1) · vivitrol (1)
Public Health Foundation Enterprises, Inc. (2) · Finnish Institute for Health and Welfare (1) · Nantes University Hospital (1) · University of Iowa (1) · University of Pennsylvania (1)
United States (3) · Finland (1) · France (1)
Susan Buchbinder, MD (2) · Daniel Weintraub, MD (1) · Dennis P McNeilly, PsyD (1) · Donald W Black, MD (1) · Hannu Alho, Professor (1) · Tuuli Lahti, Adjunct Professor (1)
PMID 25037206, PMID 26339899, PMID 33044687, PMID 36130734, PMID 39222964
R01MH109320 (2)